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background: Alcohol septal ablation (ASA) is an alternative to septal myectomy for treatment of symptomatic hypertrophic cardiomyopathy (HCM). 
ASA provides long-term resolution of left ventricular outflow tract (LVOT) obstruction, improves functional status, and restores longevity to that 
expected in the general population. Nevertheless, patients with HCM are at a 4- to 6-fold higher risk of developing atrial fibrillation, with a reported 
incidence of 2-3% per year. We evaluated whether ASA for symptomatic HCM reduces the incidence of atrial fibrillation when compared to that 
reported in the general HCM population.
Methods: We studied 132 consecutive patients with HCM without comorbid atrial fibrillation that underwent 154 ASA procedures from 2002 to 
2011. The incidence of atrial fibrillation in follow-up was assessed through systematic chart review including electrocardiography among the cohort. 
Survival free of atrial fibrillation was estimated using Kaplan-Meier methodology.
results: Over a mean follow-up of 3.6 ± 2.7 years (maximum 11.3 years), 10 (7.6%) patients developed new-onset atrial fibrillation. Of those who 
developed atrial fibrillation, resting LVOT gradient improved from a mean of 91.2 to 10.3 mm Hg (p < 0.001), and provoked LVOT gradient declined 
from a mean of 135.3 to 20.9 mm Hg (p = 0.005). Severity of mitral regurgitation improved in 7 (70%) patients from a mean of 2.7 to 1.6 (p= 
0.002; scale: none: 0, trace: 1, mild: 2, moderate: 3, severe: 4). Left ventricular ejection fraction remained preserved in all but one patient who 
developed atrial fibrillation. Fourteen (10.6%) deaths were observed. Survival free of atrial fibrillation was estimated to be 99.1%, 93.7%, and 91.7% 
at 1, 3, and 5 years; exactly replicating survival in the HCM population that did not undergo septal reduction therapy.
conclusions: Despite relieving LVOT obstruction and improving mitral regurgitation severity via ASA, the incidence of new-onset atrial fibrillation 
was consistent with that previously observed in patients with HCM who did not undergo ASA.
